JCO: Lower dose, better efficacy-Tamoxifen benefits more women!

Breast cancer is the malignant tumor with the highest incidence of women in the world.

Breast Cancer Globally, breast cancer poses a great threat to human health, both in terms of morbidity and mortality.

It is mainly used as an adjuvant therapy for estrogen receptor-positive breast cancer in premenopausal women and some postmenopausal women.

The drug is also used for chemoprevention in women with a higher risk of breast cancer , but it also increases the risk of uterine lesions, including endometrial polyps, endometrial cancer and endometrial hyperplasia, uterine sarcoma and uterine carcinosarcoma.

Prevention but at the same time increases the risk of uterine lesions, including endometrial polyps, endometrial cancer and endometrial hyperplasia, uterine sarcoma and uterine carcinosarcoma.

Changes in mammography density are representative of the response to tamoxifen treatment.

The study is part of the Swedish mammography screening program (KARISMA Phase II trial).

Screening

The study used 20 mg treatment as the standard dose.

The study used 20 mg treatment as the standard dose.

The results showed that between October 1, 2016 and September 30, 2019, 1439 participants were recruited, 566 and 873 premenopausal and postmenopausal women, respectively.

After premenopausal women took 2.

Compared with the 20 mg standard dose group, the incidence of severe vascular symptoms (hot flashes, cold sweats, and night sweats) in the 2.

In summary, when premenopausal women take 2.

When premenopausal women took 2.

references:

Mikael Eriksson, et al.

org/doi/full/10.
1200/JCO.
20.
02598#affiliationsContainer" target="_blank" rel="noopener">Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
Leave a message here